NIB Holdings Ltd (ASX: NHF) shares have opened this week down approximately 2%.
The company is a health and medical insurance provider and has seen its share price rise by more than 30% in 2025.
However, a new report from Macquarie suggests NIB shares may now be overvalued.
Here's what the broker had to say.
Image source: Getty Images
Competitive market
In today's report from the broker, it said competitive tension caused by the proliferation of front-end technology services is making the Australian travel insurance market less profitable.
According to Macquarie, in the last two years, front-end technology offerings have been supporting the broadening of competition across the Australian travel insurance market.
This has added to the popularity of the aggregator channel which in turn has caused premium rates to contract. This is expected to continue over the near term.
The broker has an underperform rating on NIB shares.
With multiple divisions experiencing operational and environmental headwinds, we retain our cautious outlook on the stock.
Any takers for NIB travel insurance?
NHF's Travel business had Net Assets of $120.9m at Jun '25.
Within this was $107.8m of Intangible Assets (despite ~$28.6m of write-downs since COVID-19) and only $0.1m of PPE and $0.2m of Right of Use Assets
This means it owns very few physical assets – its value lies mostly in intangible assets (like brand names, software, or goodwill) rather than physical infrastructure.
Macquarie estimates that NIB Holdings travel insurance business could be worth $90-$100 million.
However the potential pool of acquirers is extremely small.
The competition is plentiful but we believe the list of potential acquirers is fairly short. The successful party will likely have an existing position in Australia to get the local synergies, brands across distribution channels other than Direct to avoid cannibalisation, and an international solution for both distribution and underwriting capacity.
The broker believes that the estimated value of the business is almost half what investors are expecting. This suggests the market may be overestimating its worth, given competitive headwinds and limited strategic fit for most acquirers.
Price target downside
Based on this guidance, Macquarie has an underperform rating and price target of $5.60.
Based on today's NIB share price of $7.38, this indicates a downside of 24.12%.
